BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap, no noise, just what matters.
Wednesday, November 18, 2026
📌 TL;DR
SELLAS' galinpepimut-S extended median overall survival to 24.0 months versus 14.7 in the Phase 3 REGAL trial of AML maintenance (HR 0.59, p=0.035); nine hours later the company commenced a $150 million underwritten offering.
Merck discontinued the entire nemtabrutinib clinical program, including three Phase 3 BELLWAVE trials, after an external data monitoring committee found the benefits may not outweigh the risks in its CLL study; no data were disclosed.
The FDA approved Genentech's Wilserdly (giredestrant) with everolimus for ESR1 mutated, ER positive, HER2 negative advanced breast cancer Monday evening; the all oral combination cut the risk of progression or death 62% in the Phase 3 evERA trial.
The FDA granted accelerated approval to GSK's Nelkarmi (neladalkib) for previously treated ALK positive lung cancer Tuesday evening, ten days ahead of its November 27 target date.
Corbus' oral CB1 inverse agonist CRB-913 cut weight 5.0% versus placebo at 12 weeks at its top dose in Phase 1b CANYON-1, and Rhythm's setmelanotide held an 18.8% mean BMI reduction at two years in the TRANSCEND extension.
Tape: SLS +156.4% on REGAL, SMMT −9.7% extending the post CRL slide, RYTM +8.5% after the two year data.
⚡ Executive Takeaway
For two weeks the argument here has been that the market stopped paying for Phase 3 wins. Tuesday it paid, and the seller showed up nine hours later. SELLAS held a 156.4% gain through the close on a survival benefit in AML maintenance, the kind of result this tape has been discounting all month, and then filed to sell $150 million of stock before the pop was a day old. That sequencing is the tell. Management teams watched Helus, Amylyx and Viking give back their wins inside a session, and the lesson they took is that a data pop is an exit window, not a base. The offering will price into Wednesday's session, and the clearing price, not Tuesday's close, is the real grade of this data. If the deal holds anywhere near the close, the window for winners has actually reopened. If it clears far below, the counting standard still rules and SELLAS just proved it from the other side.
🧬 The AML Win That Finally Got Paid
SELLAS' galinpepimut-S extended median overall survival to 24.0 months versus 14.7 in Phase 3 REGAL, and the stock held a 156.4% gain into the close. SLS
REGAL randomized 126 AML patients in second or later complete remission after salvage therapy, all ineligible for transplant, to maintenance with the WT1 targeting immunotherapeutic or investigator's choice of best available treatment. At the prespecified 80 death analysis the hazard ratio was 0.59, a 41% reduction in the risk of death in a setting with no approved maintenance standard. Read the fine print before extrapolating: the trial was open label against a mixed comparator, the release gives no confidence interval and no secondary endpoints yet, and the BLA is planned for the first half of 2027 with the FDA meeting on an accelerated filing strategy still ahead. Then the other shoe: at 4:01 pm SELLAS commenced a $150 million underwritten offering, J.P. Morgan and TD Cowen on the books, with a $22.5 million option on top. Nine hours from topline to term sheet.
REGAL at 80 deaths | GPS maintenance | Best available treatment |
|---|---|---|
Median overall survival | 24.0 months | 14.7 months |
Hazard ratio, death | 0.59 (p=0.035) | reference |
Regimen | GPS monotherapy | observation, HMA, venetoclax or low dose cytarabine |
🚫 Merck Walks Away From an Entire Phase 3 Program
Merck discontinued nemtabrutinib across its entire clinical program after an external data monitoring committee found the benefits may not outweigh the risks in the Phase 3 CLL study. MRK
The flag came from BELLWAVE-011, and after reviewing the data in its totality Merck shut down not just that trial but the whole program, naming Phase 3 BELLWAVE-008 and BELLWAVE-010 alongside it. No numbers were disclosed; analyses are ongoing and results are promised to the scientific community. Nemtabrutinib was Merck's non covalent BTK inhibitor, the class built for patients who progress on covalent BTK drugs, and a benefit risk stop at the data committee stage is the hardest kind of ending because it forecloses the subgroup salvage a missed efficacy endpoint sometimes allows. The release crossed at 4:15 pm, after the close. Wednesday is the first session where the market prices Merck's hematology pipeline without it.
🎗 An All Oral Answer to Endocrine Resistance
The FDA approved Genentech's Wilserdly (giredestrant) with everolimus for ESR1 mutated, ER positive, HER2 negative advanced breast cancer, an approval that crossed Monday evening. RHHBY
In the Phase 3 evERA trial the all oral combination cut the risk of progression or death 62% versus standard endocrine therapy plus everolimus (hazard ratio 0.38, 95% confidence interval 0.27 to 0.54, p<0.0001) in patients previously treated with a CDK4/6 inhibitor. The indication requires an FDA authorized test for the ESR1 mutation, and Genentech says the drug will be available in the coming weeks. The date to circle is November 30: giredestrant's separate adjuvant application, based on the Phase 3 lidERA study, is already under priority review with a decision due that day, the same day as Vertex's povetacicept. An oral regimen that works after CDK4/6 progression reshapes second line sequencing, and the adjuvant decision two weeks out decides whether this becomes a franchise.
⚖️ ObesityWeek Closed Its Non Incretin Ledger
Corbus' oral CB1 inverse agonist cut weight 5.0% versus placebo at 12 weeks at its top dose, and Rhythm's setmelanotide held an 18.8% BMI reduction at two years, while the market paid only one of them. CRBP | RYTM
Both releases crossed Monday and both belong to the non incretin map being drawn around the GLP-1 incumbents. CANYON-1 randomized 254 non diabetic adults across placebo and three CRB-913 doses; placebo came in at exactly 0.0%, the 60 mg arm at 5.0% (p<0.0001), with no serious treatment related events and no suicidality, the signal that killed the first CB1 generation. The cost sits in the discontinuations: 13.1% and 12.9% of the two higher dose arms stopped for adverse events, against 4.5% on placebo. Corbus closed flat on data day and gave back 10.8% Tuesday. Rhythm's two year TRANSCEND extension, with BMI reductions near 19% sustained in acquired hypothalamic obesity and a 17 expert consensus definition published to build the diagnosed market, drew the opposite verdict: up 8.5% Tuesday, the first full session after the data.
📋 Quick Hits
The FDA's Nelkarmi approval came under the accelerated pathway on response rates from the single arm ALKOVE-1 trial: 49% after alectinib only and 32% after two or more ALK TKIs plus chemotherapy. Neladalkib came to GSK with the Nuvalent acquisition; the 5:00 pm release makes Wednesday the first session to price it. GSK
BioXcel is three days past the November 14 action date on the Igalmi at home sNDA with no announced decision. Searches and the company's investor page turn up nothing newer than August; we keep checking every build. BTAI
Karyopharm's XPOVIO plus ruxolitinib sNDA in myelofibrosis was accepted with a June 28, 2027 action date, based on the Phase 3 SENTRY trial. The context is the story: the company is in Chapter 11, its plan expects existing equity to hold no value, and any approval would belong to the reorganized company planned under the Ayrmid merger.
Incyte's Povofortay (povorcitinib) was approved in Europe as the first once daily oral treatment for moderate to severe hidradenitis suppurativa, per the company's Monday release. INCY
Amneal won European approval for Adcomfo, an omalizumab biosimilar to Xolair, per Tuesday's release; Biogen presented five year lecanemab data at CTAD Monday evening, and Biogen and Ionis reported increasing clinical benefit at two years for diranersen in early Alzheimer's disease, per Tuesday evening's release headlines. AMRX | BIIB | IONS
Verified absences, with scope: no closing releases yet from Windward, Rezolute, Surrozen or InspireMD (the "Rezolute closing" item circulating is the April 2025 offering, a different deal); no final Chinese biotech export control catalogue two days after the comment window closed; no CagriSema decision yet in the Q4 window.
👀 What To Watch Today
Wed, Nov 18: First Merck session after the nemtabrutinib discontinuation, Merck
Wed, Nov 18: SELLAS' $150 million offering is expected to price, SELLAS
Thu, Nov 19: Biohaven's BHV-1530 oral presentation at EORTC-NCI-AACR, Biohaven
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The complete REGAL dataset and its open questions, with the offering terms
Merck's BELLWAVE trial inventory and what the eDMC language does and does not say
Wilserdly's label, the evERA numbers and the November 30 adjuvant decision
The CANYON-1 dose table, Rhythm's two year data and the day's movers with context
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 Nine hours from topline to term sheet: what the SELLAS offering says about the window for winners
💊 The eDMC stop: how a benefit risk ending lands differently than a miss, and who inherits the BTK patients
📊 After ObesityWeek: the non incretin map, and why sorting patients now beats adding percentage points
🎯 Plus the week's coming catalysts, with the full calendar returning in Friday's edition

